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Abstract
Background: Kenya introduced a pentavalent vaccine including the DTP, Haemophilus influenzae
type b and hepatitis b virus antigens in Nov 2001 and strengthened immunization services. We
estimated immunization coverage before and after introduction, timeliness of vaccination and risk
factors for failure to immunize in Kilifi district, Kenya.
Methods: In Nov 2002 we performed WHO cluster-sample surveys of >200 children scheduled
for vaccination before or after introduction of pentavalent vaccine. In Mar 2004 we conducted a
simple random sample (SRS) survey of 204 children aged 9–23 months. Coverage was estimated by
inverse Kaplan-Meier survival analysis of vaccine-card and mothers' recall data and corroborated
by reviewing administrative records from national and provincial vaccine stores. The contribution
to timely immunization of distance from clinic, seasonal rainfall, mother's age, and family size was
estimated by a proportional hazards model.
Results: Immunization coverage for three DTP and pentavalent doses was 100% before and 91%
after pentavalent vaccine introduction, respectively. By SRS survey, coverage was 88% for three
pentavalent doses. The median age at first, second and third vaccine dose was 8, 13 and 18 weeks.
Vials dispatched to Kilifi District during 2001–2003 would provide three immunizations for 92% of
the birth cohort. Immunization rate ratios were reduced with every kilometre of distance from
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home to vaccine clinic (HR 0.95, CI 0.91–1.00), rainy seasons (HR 0.73, 95% CI 0.61–0.89) and
family size, increasing progressively up to 4 children (HR 0.55, 95% CI 0.41–0.73).
Conclusion: Vaccine coverage was high before and after introduction of pentavalent vaccine, but
most doses were given late. Coverage is limited by seasonal factors and family size.
Background
Haemophilus influenzae type b (Hib) is a leading cause of
meningitis, septicaemia and pneumonia in young chil-
dren [1]. Among children aged <5 years, the annual inci-
dence of Hib meningitis in the Gambia was 60/100,000
[2] and of invasive Hib disease in Kenya was 66/100,000
(Cowgill et al, submitted) prior to vaccine introduction.
In the Gambia Hib-conjugate vaccine had an efficacy of
95% against invasive Hib disease and prevented >20% of
episodes of radiologically-confirmed pneumonia [3].
Hepatitis B virus (HBV) causes 0.5–1.2 million deaths glo-
bally each year through chronic hepatitis, cirrhosis and
hepatocellular carcinoma [4]. The mean prevalence of
chronic HBV infection in Africa is 10.4% but reported
prevalence varies depending on communities [5-8]. In the
Gambia, among 9-year-old children who received the
Hepatitis B vaccine in infancy, vaccine efficacy was 83%
against infection with HBV and 93% against chronic
infection [8].
In 2001 the Global Alliance for Vaccines and Immuniza-
tion (GAVI) offered financial support to developing coun-
tries to introduce new vaccines and strengthen
immunization services. With these funds, Hib-conjugate
and Hepatitis B vaccines were introduced into the EPI
schedule in Kenya combined with diphtheria, pertussis
and tetanus (DPT) antigens as a pentavalent vaccine
administered at 6, 10 and 14 weeks of age. Timely admin-
istration of these new antigens was considered essential,
as invasive Hib disease incidence peaks at 4 months
(Cowgill et al, submitted) and vaccination beginning at 6
weeks can prevent early horizontal HBV infection [9].
Cash support of over $11 million for immunization serv-
ices, particularly for new vaccine clinics, expansion of
storage capacity, maintenances of the cold chain, health
workers training and community mobilization was
designed to increase immunization coverage. At the same
time, however, the package volume of the pentavalent
vaccine was substantially greater than that of DTP alone,
creating potential problems for cold-chain storage and
delivery mechanisms, which might have decreased immu-
nization coverage. We set out to determine whether
immunization coverage had increased or decreased, to
describe the timeliness of immunization and to explore
which factors were associated with delayed or missed vac-
cination, after the introduction of the Hib vaccine. One
year after Hib vaccine introduction in Kilifi we observed
no detectable impact on Hib disease incidence. Several
children who had been admitted to Kilifi Hospital with
invasive Hib disease had not been fully vaccinated despite
being eligible (Cowgill et al, submitted). We therefore
conducted the cluster-sample survey to determine
whether the delay in vaccine impact was attributable to
imperfect coverage.
Methods
Kilifi District, the second poorest in the country, is located
on the Indian Ocean Coast of Kenya [10]. In the 1999
Kenya Government census it had a population of
544,303. A demographic surveillance study (DSS) was
established in 2000 in the sub-population of 210,000 liv-
ing closest to Kilifi District Hospital, with 4–6 monthly
enumeration and registration of vital events. This was the
target population for our surveys. Ethical approval for the
study was granted by the Kenya Medical Research Institute
(KEMRI) National Review Ethical Committee. Verbal con-
sent was sought from participants during invitation to
take part in the study. Pentavalent vaccine was distributed
rapidly in Kilifi District, and all old DPT vaccine stock
recalled, during October 2001. Immunizations are
recorded on vaccine cards but children who attend for vac-
cination without their cards are immunized nonetheless.
Package volume
We measured the dimensions of the DPT package and the
two packages of the pentavalent vaccine that replaced it.
WHO cluster coverage survey
We simultaneously conducted two WHO-EPI cluster cov-
erage surveys among children of different ages during
November-December 2002. The first survey sampled chil-
dren who were old enough to have completed the 3-dose
DPT series prior to introduction of pentavalent vaccine
(born between 25th June 2000 and 24th June 2001); the
second sampled younger children who should have
received 3 doses of pentavalent vaccine (born after 19th
September 2001 and at least 14 weeks of age at time of
survey).
We followed the WHO-EPI Coverage Survey Manual [11],
using the DSS to select at random the starting household
for each of 30 clusters. Fieldworkers continued sampling
adjacent households until 7 appropriately-aged children
were identified in each cluster. Vaccine records or par-BMC Public Health 2006, 6:132 http://www.biomedcentral.com/1471-2458/6/132
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ents'/guardians' (usually mothers') histories were tran-
scribed to WHO-designed forms at the household by
trained fieldworkers and double-entered onto a WHO-
designed computer programme (WinCosas, Vaccines &
Biologicals, WHO, Geneva).
SRS coverage survey
In March-April 2004 we did a second survey by simple
random sampling (SRS) of the DSS database. We ranked
>9000 resident children aged 9–23 months (born
between 1st Jun 2002 and 31st Jul 2003) by applying ran-
dom numbers. Starting with the highest ranked child we
invited children to take part sequentially until 100 of each
sex had been recruited. We asked participants to attend
appointments at the research unit where their immuniza-
tion records were transcribed and digitally scanned. If no
immunization record was available or the record was
incomplete, the mothers were interviewed using a stand-
ard questionnaire. Site of immunization was used to iden-
tify the antigens from recall data e.g. only pentavalent
vaccine is given into the left lateral thigh. To evaluate the
sensitivity of mothers' recall we also interviewed two
mothers each day whose children had complete immuni-
zation records. The very high response by participants
ensured minimal sample bias. Card and questionnaire
data were double-entered in Epi-Info (Centers for Disease
Control and Prevention, Atlanta). We chose a simple ran-
dom sample because households in Kilifi are dispersed
not clustered in villages [12]; because a DSS register was
available; and because a SRS of similar size to the cluster
surveys would provide more precise estimates of coverage
[13].
Coverage by clinic register and administrative methods
The numbers of pentavalent vaccine doses delivered to
Kilifi District between October 2001 and December 2003
were obtained from the Kenya Expanded Programme on
Immunization (KEPI) national stores in Nairobi and pro-
vincial stores in Mombasa. The monthly returns to KEPI
of the number of doses recorded as given at vaccine clinics
in Kilifi District were also collated for the years 2002–3.
Pentavalent vaccine is packaged as a two-dose vial and
unused vials must be discarded at the end of each day. We
assumed that the daily probability of wasting a single dose
in a functioning clinic is 0.5. With 30 vaccination clinics
working 20 days a month, there are 7200 vaccine-clinic
days leading to 3600 wasted doses per year. As 134,800
doses were delivered to the district in 2002–2003, this
suggests a minimum wastage of 5.3%. To adjust for losses
due to distribution problems we estimated a total wastage
of 10%.
Population denominator and Geographic Information 
Systems (GIS) analysis
Annual population growth in rural Kenya in 2003 was 3%
and the crude birth rate was 38.6/1000 [14]. We estimated
the population of Kilifi District to be 594,774 and
612,618 in the years 2002 and 2003, with birth cohorts of
22,958 and 23,647 respectively. After adjustment for a
neonatal mortality rate of 45/1000 live births, this yielded
vaccine cohorts of 21,925 and 22,583 children. We digit-
ally mapped subjects' residences in the DSS area and the
vaccination clinics in the whole of Kilifi District. The
shortest distance from each household to the nearest vac-
cine clinic was determined directly using ArcGIS v9.0
(ESRI, Redlands, CA).
Data was analysed using STATA v8.2 (Stata Corp, College
Station TX). Immunization prevalence was determined
for the date of the survey. Timeliness of pentavalent vac-
cine uptake was determined in the SRS survey using an
inverse Kaplan-Meier survival function [15]. In unvacci-
nated children the time to the next eligible dose was cen-
sored on the date of survey. Precision estimates for the
cluster survey were modified by a design effect of 2.6 cal-
culated from the data [13]. Administrative coverage was
the annual number of doses delivered to vaccine clinics
(adjusted for 10% wastage), or administered at clinics,
divided by the yearly vaccine cohorts.
A Cox proportional hazards model was fit to recurrent
vaccination data to determine the contributions of sex,
clinic distance, family size, mother's age and rainfall sea-
son to immunization rates. Survival periods were synchro-
nized to start 28 days before each dose was due and
separate survival times were entered into the data for each
of the three doses for each child, tied by child in a shared-
frailty model [16]. Variables were excluded if they did not
contribute significantly to model fit (i.e., Likelihood Ratio
Test p value >0.05). We tested the proportional hazards
assumption using Schoenfeld residuals and by examina-
tion of Cox predicted and log-log curves. The resultant
hazard ratios are here called age-specific immunization
rate ratios or, for brevity, immunization ratios.
Kilifi has rainy seasons from April to July and October to
November during which the mean precipitation meas-
ured in daily rainfall records in Kilifi from 1993–2004 is
= 3 mm. In the other six months mean daily precipitation
is <3 mm. A survival period was categorised as rainy if it
began during a rainy season month. We also constructed,
for each immunization event, the mean daily rainfall for
14 days before each dose was due.BMC Public Health 2006, 6:132 http://www.biomedcentral.com/1471-2458/6/132
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Results
Package volume
Pentavalent vaccine is presented in bulk as two packages,
18 cm × 15 cm × 4 cm, providing a total of 200 doses; it
replaced a single 500-dose package of DTP, 13 cm × 13 cm
× 5 cm. The package volume of the new vaccine is 6.4
times greater per dose than the old vaccine.
WHO cluster coverage survey
The median (range) age of children born before and after
pentavalent vaccine introduction was 695 (524–897) and
251 (99–446) days, respectively; children were born
between 25th Jun 2000–20th Jun 2001 and 20th September
2001–1st September 2002 in the two samples. Vaccine
cards were retained by 153 (75%) of 203 children before
and 181 (88%) of 206 children after pentavalent vaccine
introduction (p < 0.001). Combining evidence of vaccine
cards and mothers' histories, immunization coverage for
three doses of vaccine was 100% (95% CI 95–100) and
91% (95% CI 83–96) in the two samples, respectively
(Table 1). For analysis of coverage over time we examined
immunization coverage only in children with vaccine
cards and at the fixed age of 14 weeks (for doses 1 and 2)
or 18 weeks (for dose 3). The coverage for the first dose
was 84% (128/153) before, and 93% (168/181) after
introduction of pentavalent vaccine (p = 0.01); for the
third dose it was 48% (74/153) and 60 % (108/181)
respectively (p = 0.04). Immunization coverage for the
second dose did not differ significantly. In both samples
the median age at immunization was greater than the
upper limit of the target age range for immunization
(Table 1).
SRS coverage survey
Of two hundred children invited to participate four were
late attending the hospital during which interval replace-
ment children were recruited. Of 204 participants, 105
(52%) were male and 165 (81%) had vaccine cards. The
median (range) age of mothers and children was 28 years
(17–51) and 460 days (277–659), respectively; the chil-
dren were born between 25th June 2002 and 30th June
2003. Immunization coverage is summarised in Table 2.
The sensitivity of immunization histories was estimated
in interviews with 18 mothers; all correctly recalled the
first dose of vaccine, 17 (94%) recalled the second dose
and 16 (88%) recalled the third dose. Timeliness of vacci-
nation is illustrated in the inverse Kaplan-Meier survival
curves (Figure 1) and summarised at immunization target
dates in Table 3.
Coverage by clinic register and administrative methods
Clinic registers recorded sufficient immunizations of first,
second and third doses of pentavalent vaccine to cover
81%, 78% and 71% of children in Kilifi District, respec-
tively. The numbers of doses of vaccine distributed to Kil-
ifi District from national KEPI stores in 2002 and 2003
were 69,000 and 65,800, respectively; from provincial
KEPI records the numbers distributed were 73,300 and
64,600, respectively. Administrative coverage estimates
averaged over three doses of vaccine (assuming 10% wast-
age) were 91% and 93%, by national and provincial
records, respectively. For comparison, the mean coverage
estimates across all three doses in the SRS survey and
clinic register survey were 90% and 76% respectively.
Factors affecting immunization success
There were 30 government vaccination clinics in the dis-
trict and 8 within the DSS (Figure 2). The median direct
distance to the nearest clinic was 4.19 km (range 0.24–
10.1 km). In univariate analyses, season, recent rainfall,
distance to clinic, mother's age and family size were each
associated with the rate of immunization (Table 4); recent
rainfall and mother's age did not contribute to the final
multivariable model. The effect of family size showed a
gradient which reached a plateau at 4 children. There were
no significant interactions between the variables in the
final model.
Table 1: Immunization coverage by WHO EPI cluster coverage survey in Nov-Dec 2002 in Kilifi District, Kenya
Before pentavalent (N = 203)* After pentavalent (N = 206)†
Target 
age
No. with 
card 
evidence
No. with 
history 
evidence
Coverage 
by card 
or history
Age at immunization 
(days)‡
No. with 
card 
evidence
No. with 
history 
evidence
Coverage 
by card 
or history
Age at immunization 
(days)‡
vaccine 
dose
range 
(days)
of vaccine of 
vaccine§
(%) median range of vaccine of 
vaccine§
(%) median range
dose 1 39 – 45 150 53 100 54 1–615 176 30 100 53 0–268
dose 2 67 – 73 143 60 100 90 45–657 159 38 96 86 42–268
dose 3 95 – 101 138 65 100 123 78–699 136 51 91 120 70–339
* Children born after 24 June 2000 and before 25 June 2001, aged 18 -30 months, of whom 153 retained vaccine cards
† Children born after 19th September 2001 and at least 14 weeks prior to survey of, aged 3.5 – 12 months, whom 183 retained vaccine cards
‡ Only calculated in children with card evidence
§Includes doses from children with cards who have missing entries for this dose but whose mothers report that they have received the dose nonethelessBMC Public Health 2006, 6:132 http://www.biomedcentral.com/1471-2458/6/132
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Discussion
The cluster survey showed that immunization coverage
for three doses of DPT/pentavalent vaccine in Kilifi in
2001–2002 was very high (91–100%). The results were
underpinned by good retention of vaccine cards in
younger children (88%) and reasonable retention in older
children (75%). Among older children, only three of 153
children with a vaccine card did not have written evidence
confirming receipt of DPT1; among the mothers of these
three children, and the 50 children who did not have a
vaccine card, every single one reported that her child had
received this dose. Results for pentavalent 1 in the
younger sample were similar. In both samples an
extremely high proportion of mothers reported that their
children had received doses two and three.
It is clear from the vaccine card evidence alone that immu-
nization coverage was high but we were concerned about
the validity of the mothers recall data which was used to
estimate coverage more accurately. The SRS survey
attempted to reduce the reliance on mothers' histories and
introduced detailed interview about the immunizations.
We reasoned that mothers given an appointment at the
hospital would have time to find misplaced cards [17] and
that interviews conducted at hospital, closely monitored
by the investigator, would be superior to field interviews.
In the cluster-survey many children were vaccinated long
after the target date and some appeared to have been vac-
cinated too early. In the SRS survey potential transcription
errors among outlier dates were counterchecked against a
stored digital image of vaccine document. In a previous
study from Egypt, data errors were more frequently attrib-
utable to interviewer factors and data processing than to
maternal recall [17].
Immunization coverage in the SRS survey was also high;
88% of children aged 9–23 months had received three
doses of pentavalent vaccine. Despite differences in the
methodology, and the fact that the median age of children
in the SRS survey was lower, the proportion of children
with cards was no greater than in the first survey. As antic-
ipated, however, coverage estimates among those without
vaccine cards were slightly lower using hospital-based
interviews. The differences between the two surveys, how-
ever, may have resulted from changes in coverage over
time.
Validation of mothers' histories against complete card
entries suggested that mothers in Kilifi have some loss of
recall for second and third vaccine doses, indicating that
we have slightly underestimated coverage for doses two
and three by including recall data. However, in an area
with incomplete vaccine card retention coverage is esti-
mated most accurately by combining both card and his-
Pentavalent vaccine uptake among 204 in the simple random  survey in Kilifi District, Kenya, by inverse Kaplan-Meier sur- vival function Figure 1
Pentavalent vaccine uptake among 204 in the simple random 
survey in Kilifi District, Kenya, by inverse Kaplan-Meier sur-
vival function
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Table 2: Immunization coverage for selected antigens by simple random sample survey in Mar – Apr 2004 in Kilifi District, Kenya
Card evidence in children with 
cards (N = 165)
History evidence in children 
without cards (N = 39)
Card or history evidence 
combined in all children (N = 
204)
Antigen number 
vaccinated
% vaccinated number 
vaccinated
% vaccinated number* 
vaccinated
% vaccinated 95 % CI
BCG 164 99 31 79 196 96 92 – 98
Birth polio 112 68 29 74 173 85 79 – 89
Polio 1 163 99 29 74 193 95 91 – 97
Polio 2 158 96 26 67 189 93 88 – 96
Polio 3 150 91 23 59 177 87 81 – 91
Penta 1 163 99 29 74 193 95 91 – 97
Penta 2 159 96 27 69 189 93 88 – 96
Penta 3 150 91 24 62 179 88 82 – 92
* Includes children with vaccine cards who have missing entries for vaccines but whose mothers report that they have received the vaccine nonetheless.BMC Public Health 2006, 6:132 http://www.biomedcentral.com/1471-2458/6/132
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tory data [17]. To analyse only written evidence of
immunization from the whole sample would significantly
underestimate coverage since vaccine cards are not neces-
sarily retained after the vaccine schedule is completed; to
analyse only those who retained a card would overesti-
mate coverage by excluding children who never attend
hospital facilities. We included mother's recall data in the
analysis of vaccination timeliness too because we expected
that mothers who did not retain vaccine cards would be
less likely to adhere punctually to the vaccine schedule.
This turned out to be the case (analysis not shown).
To examine small changes in immunization coverage over
time, evidence from mother's memories is invalidated by
recall bias. Restricting to card data, and controlling for the
potentially confounding effect of age by analysing cover-
age at 14 or 18 weeks of age we found that coverage was
significantly greater for doses 1 and 3 after introduction of
Pentavalent vaccine than before. This improvement
occurred despite the fact that logistic requirements for
Pentavalent vaccine distribution were greater because the
per dose package size was more than six times greater than
for DTP vaccine alone.
Administrative coverage estimates were slightly higher
than those obtained from direct surveys of children, as has
been observed elsewhere in Africa [18,19]. The low cover-
age estimate from clinic registers suggests incomplete
reporting at clinic level. Reliance on reported data has
more frequently led to overestimation of immunization
coverage by developing countries, when compared to sur-
vey data [20]. Administrative coverage calculations are
particularly sensitive to estimates of vaccine wastage.
Assuming that the SRS survey coverage is accurate, and
that inaccuracies in the national and provincial adminis-
trative estimates are due entirely to vaccine wastage, we
can derive indirect estimates of vaccine wastage of 10.9%
and 12.9% respectively, slightly over twice the acceptable
level for the vaccine.
For a disease like Hib which peaks early in infancy
(Cowgill et al, submitted), timeliness of immunization
will increase the directly protective effect of immuniza-
tion. Two doses of Hib-conjugate vaccine are considered
sufficient to induce protection against disease [21]. The
median age of immunization with two doses in the SRS
survey was 3 months, and it was not until after 9 months
Map of the sub-locations of the Kilifi DSS showing vaccine  clinic locations and 204 children's residences in the simple  random sample survey Figure 2
Map of the sub-locations of the Kilifi DSS showing vaccine 
clinic locations and 204 children's residences in the simple 
random sample survey
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Table 3: Pentavalent vaccine coverage at different ages among children in Kilifi District estimated from vaccine-card or mother's recall 
data
Age of child§
Dose of vaccine 6 weeks 10 weeks 14 weeks 18 weeks 12 months
Dose 1 22% 73% 85% 90% 93%
Dose 2 0 15% 63% 81% 91%
Dose 3 0 0 9% 50% 87%
§Children born between 1st Jun 2002 and 31st Jul 2003, aged 9 – 23 months, in SRS coverage survey (N = 204)BMC Public Health 2006, 6:132 http://www.biomedcentral.com/1471-2458/6/132
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of age that 90% of children were immunized with a sec-
ond dose of vaccine. Clearly the protection of a substan-
tial risk group aged <3 months depends entirely on
indirect vaccine protection.
In Egypt immunization coverage declined with increasing
distance from the vaccination clinics [22]. We observed a
similar effect with distance in Kilifi, but the size of this
effect was small probably because the median distance to
the nearest vaccine clinic was 4 km and therefore vaccina-
tion is geographically accessible to the majority of chil-
dren. Immunization was more strongly associated with
annual patterns of rainfall than with the actual precipita-
tion records from the 14 days before each dose was due.
This suggests that longer term seasonal changes, such as
the requirement to plant crops at a remote small-holding
or the increase in costs of public transport fares, which
occur at predictable calendar points in relation to antici-
pated rainfall patterns, are greater impediments to immu-
nization than the rain itself. Parents of large families are
less likely to immunize their children. This may simply
reflect an association between use of family planning and
use of immunization services, or it may indicate that
mothers at home are unable to bring their infant for
immunization because of the practical difficulties and
expense of having other children at home. Kilifi is a poor
district in Kenya with high infant mortality rate; better
coverage would be expected in other districts and Kenya as
a whole.
Conclusion
In Kilifi District, immunization coverage for two and three
doses of the Hib-conjugate and Hepatitis B vaccines at 12
months of age is 91% and 88%, respectively. Coverage
estimates derived from national and provincial distribu-
tion records corroborate these results. Immunization cov-
erage has not declined over the period of pentavalent
vaccine introduction despite a 6-fold increase in the trans-
port and storage requirements. However, at the age of 3
months, only half of all children had received two doses
of vaccine. To improve timely coverage it will be necessary
to target children from larger families and to explore the
impediments to vaccination that occur during seasonal
rains.
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three children in the family 0.62 (0.45–0.87) 0.61 (0.43–0.87)
four or more children in 
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0.53 (0.41–0.70) 0.55 (0.41–0.73)
* Survival time, the 28 days before the vaccine due date, began during a rainy season month defined as a mean daily rainfall ≥ 3 mm throughout the years 
1992–2004.
†mean rainfall in the 14 days before the vaccine was due
‡ These variables were excluded from the multivariable model because a Likelihood Ratio Test of their contribution to the model yielded p > 0.05Publish with BioMed Central    and   every 
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